Pharma major Lupin Limited announced that it has received approval for its propranolol hydrochloride extended-release (ER) capsules, 60 mg, 80 mg, 120 mg and 160 mg from Health Canada.
Lupin is the first generic company to receive an approval for generic Inderal-LA capsules for the Canadian market and the product has been approved and will be manufactured from the company's Pithampur Unit-2 facility.
Lupin’s propranolol hydrochloride extended-release (ER) capsules, 60 mg, 80 mg, 120 mg and 160 mg, are the generic version of Inderal-LA capsules, 60 mg, 80 mg, 120 mg and 160 mg of Pfizer Canada ULC, and are indicated in the treatment of hypertension and for the prophylaxis of angina pectoris.
Propranolol hydrochloride ER capsules had an annual sales of approximately CAD 8.6 million (MAT December 2018 IQVIA).
